> top > docs > PMC:7274968 > spans > 4310-4574 > annotations

PMC:7274968 / 4310-4574 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
72 150-168 Gene denotes estrogen receptors Gene:2069
73 170-172 Gene denotes ER Gene:2069
74 176-180 Gene denotes HER2 Gene:2064
79 58-66 Species denotes patients Tax:9606
85 88-110 Disease denotes invasive breast cancer MESH:D001943

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T8 97-103 Body_part denotes breast http://purl.org/sig/ont/fma/fma9601
T9 150-158 Body_part denotes estrogen http://purl.org/sig/ont/fma/fma83376

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T4 97-103 Body_part denotes breast http://purl.obolibrary.org/obo/UBERON_0000310

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T24 88-110 Disease denotes invasive breast cancer http://purl.obolibrary.org/obo/MONDO_0006256
T25 97-110 Disease denotes breast cancer http://purl.obolibrary.org/obo/MONDO_0007254
T26 104-110 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T55 12-14 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T56 97-103 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
T57 150-168 http://purl.obolibrary.org/obo/PR_000007204 denotes estrogen receptors
T58 170-172 http://purl.obolibrary.org/obo/PR_000007204 denotes ER

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T5 150-158 Chemical denotes estrogen http://purl.obolibrary.org/obo/CHEBI_50114
T6 246-255 Chemical denotes endocrine http://purl.obolibrary.org/obo/CHEBI_24621

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T13 97-110 Phenotype denotes breast cancer http://purl.obolibrary.org/obo/HP_0003002

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T36 0-264 Sentence denotes In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer <30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy.